2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Non-Biological Therapies, Chemotherapy, Devices, Pharmacology, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4201 ABO mismatch in the modern era: Post-transplant cyclophosphamide reduces alloimmunity and minor mismatch no longer confers excess NRM

Shaya Alimoghadam, MD, Robert Lowsky, MD2, John Tamaresis, PhD3, Ying Lu, PhD4, Hrishikesh Srinagesh, MD, MSCR5, Amelia Scheck6, Snehit Prabhu, PhD7, Sally Arai, MD8, Sushma Bharadwaj, MD9, Saurabh Dahiya, MD, FACP10, Hany Elmariah, MD,MS11, Mathew J. Frank, MD, PhD12, Laura Johnston, MD13, Lekha Mikkilineni, MD, MA14, Lori Muffly, MD15, Robert Negrin, MD16, Andrew Rezvani, MD17, Judith Anne Shizuru, MD, PhD18, Surbhi Sidana, MD19, Melody Smith, MD,MS20, Wen-Kai Weng, MD, PhD21, David Miklos, MD, PhD22, Vanessa E Kennedy, MD23
1 Stanford University School of Medicine, Stanford, California, United States
2 Stanford University School of Medicine, Stanford, California, United States
3 Stanford University School of Medicine, Stanford, California, United States
4 Stanford University School of Medicine, Stanford, California, United States
5 Stanford University School of Medicine, Stanford, California, United States
6 Stanford University School of Medicine, Stanford, California, United States
7 Stanford University School of Medicine, Stanford, California, United States
8 Stanford University School of Medicine, Stanford, California, United States
9 Stanford University School of Medicine, Stanford, California, United States
10 Stanford University School of Medicine, Stanford, California, United States
11 Stanford University School of Medicine, Stanford, California, United States
12 Stanford University School of Medicine, Stanford, California, United States
13 Stanford University School of Medicine, Stanford, California, United States
14 Stanford University School of Medicine, Stanford, California, United States
15 Stanford University School of Medicine, Stanford, California, United States
16 Stanford University School of Medicine, Stanford, California, United States
17 Stanford University School of Medicine, Stanford, California, United States
18 Stanford University School of Medicine, Stanford, California, United States
19 Stanford University School of Medicine, Stanford, California, United States
20 Stanford University School of Medicine, Stanford, California, United States
21 Stanford University School of Medicine, Stanford, California, United States
22 Stanford University School of Medicine, Stanford, California, United States
23 Stanford University School of Medicine, Stanford, California, United States

Introduction:

In allogeneic hematopoietic cell transplantation (alloHCT), the presence of donor-recipient ABO minor mismatch has historically been associated with inferior overall survival (OS) and increased non-relapse mortality (NRM), as reported by Logan et al. In recent years, alloHCT practice has evolved to include increased use of post-transplant cyclophosphamide (PTCy)-based Graft-versus-host disease (GVHD) prophylaxis. Based on the biology of passenger lymphocyte syndrome (PLS), direct antiglobulin test (DAT) surveillance was implemented at our institute in minor and bidirectional ABO-mismatched recipients as a marker of ABO-directed alloimmunity. Given the changing landscape of GVHD prophylaxis, we evaluated the impact of ABO mismatch on clinical outcomes and DAT positivity in the modern transplant era.

Methods:

We retrospectively studied consecutive alloHCT recipients transplanted at Stanford University from 2011 to 2025. Minor and bidirectional ABO-mismatched recipients underwent DAT surveillance at days 7, 9, 11, 13, and 15 post-alloHCT. Multivariable logistic regression identified factors associated with DAT positivity. Fine-Gray competing-risk models evaluated NRM, treating relapse as a competing event. Covariates included patient and donor age, sex mismatch, disease histology, donor type (related vs unrelated), graft source (peripheral blood vs bone marrow), conditioning intensity, CD34+ cell dose, and GVHD prophylaxis (PTCy-containing, calcineurin inhibitor–based, or TLI/ATG–based).

Results:

Of 2,236 recipients, ABO compatibility was classified as matched (60.5%), major mismatch (17.0%), minor mismatch (17.6%), or bidirectional mismatch (4.9%).  Compared with ABO-matched alloHCT, minor mismatch was no longer associated with increased NRM at day-100 (sHR 0.74, p=0.225), 1 year (sHR 0.99, p=0.969), or 2 years post-transplant (sHR 0.96, p=0.800), and trended toward improved OS (HR 0.84, p=0.055) and reduced relapse (sHR 0.79, p = 0.065). Bidirectional mismatch, however, was associated with increased NRM at 1 year (sHR 1.77, p = 0.016) and 2 years (sHR 1.63, p = 0.027), but not by day 100 (sHR 1.57, p = 0.159); OS and relapse were not significantly different. Major mismatch did not impact OS, relapse, or NRM at day 100, 1 year, or 2 years.

Of 503 minor and bidirectional patients, 322 (64.1%) had a DAT available; 184 (57.1%) were DAT negative and 138 (42.9%) were DAT positive. DAT positivity was less common following PTCy, occurring in 34.2% of PTCy recipients vs 52.0% of recipients of calcineurin inhibitor/methotrexate-based prophylaxis (p=0.01). 

In multivariate analysis, PTCy was independently associated with reduced DAT positivity compared with calcineurin inhibitor–based regimens (OR 0.40, p=0.014). Myeloid malignancy was also associated with higher odds of DAT positivity compared with lymphoid disease (OR 2.74, p=0.002), while recipient age was associated with lower odds (OR 0.97 per year, p = 0.006). Sex, donor relatedness, graft source, and CD34+ cell dose had no impact. Among minor and bidirectional patients, DAT positivity was not associated with increased NRM compared with DAT negative (sHR 0.90, p=0.694).

Conclusion:

Compared with the historical Logan et al. cohort, major and minor ABO mismatch are no longer associated with increased NRM, although bidirectional mismatch may still be associated with increased toxicity. After minor or bidirectional ABO mismatch, early DAT positivity is common but is substantially less frequent with PTCy than with conventional calcineurin inhibitor-based approaches, suggesting that PTCy may mitigate early donor-derived erythrocyte sensitization. DAT positivity was not, however, associated with NRM, although this may in part reflect early recognition and management following DAT conversion. These data support that minor ABO-mismatched donors are acceptable in the contemporary era.

Shaya Alimoghadam, MD: No relevant conflicts of interest to declare.